Risk factors analysis and stratification for microscopically positive resection margin in gastric cancer patients.
Gastrectomy
Gastric cancer
Intraoperative frozen section
Resection margins
Risk factors
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
07 May 2020
07 May 2020
Historique:
received:
19
02
2020
accepted:
12
04
2020
entrez:
9
5
2020
pubmed:
10
5
2020
medline:
7
10
2020
Statut:
epublish
Résumé
Cancer cells are often found postoperatively at surgical resection margins (RM) in patients with gastric cancer because of submucosal infiltration or hesitation to secure adequate RM. This study was designed to evaluate risk factors for microscopic positive RM and to clarify which patients should undergo intraoperative frozen section diagnosis (IFSD). Patients who underwent R0/1 gastrectomy for gastric adenocarcinoma between 2000 and 2018 in a single cancer center in Japan were studied. We divided the patients into a positive RM group and negative RM group according to the results of definitive histopathological examinations. We performed multivariate analysis to analyze risk factors for positive RM by and used the identified risk factors to risk stratify the patients. A total of 2757 patients were studied, including 49 (1.8%) in the positive RM group. The risk factors significantly associated with positive RM were remnant gastric cancer (odds ratio [OR] 4.7), esophageal invasion (OR 6.3), tumor size ≥80 mm (OR 3.9), and a histopathological diagnosis of undifferentiated type (OR 3.6), macroscopic type 4 (OR 3.7), or pT4 disease (OR 4.6). On risk stratification analysis, the incidence of positive RM was 0.1% without any risk factors, increasing to 0.4% with one risk factor, 3.1% with two risk factors, 5.3% with three risk factors, 21.3% with four risk factors, and 85.7% with five risk factors. The risk of macroscopically positive RM increased in patients who have risk factors. IFSD should be performed in patients who have four or more risk factors.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer cells are often found postoperatively at surgical resection margins (RM) in patients with gastric cancer because of submucosal infiltration or hesitation to secure adequate RM. This study was designed to evaluate risk factors for microscopic positive RM and to clarify which patients should undergo intraoperative frozen section diagnosis (IFSD).
METHODS
METHODS
Patients who underwent R0/1 gastrectomy for gastric adenocarcinoma between 2000 and 2018 in a single cancer center in Japan were studied. We divided the patients into a positive RM group and negative RM group according to the results of definitive histopathological examinations. We performed multivariate analysis to analyze risk factors for positive RM by and used the identified risk factors to risk stratify the patients.
RESULTS
RESULTS
A total of 2757 patients were studied, including 49 (1.8%) in the positive RM group. The risk factors significantly associated with positive RM were remnant gastric cancer (odds ratio [OR] 4.7), esophageal invasion (OR 6.3), tumor size ≥80 mm (OR 3.9), and a histopathological diagnosis of undifferentiated type (OR 3.6), macroscopic type 4 (OR 3.7), or pT4 disease (OR 4.6). On risk stratification analysis, the incidence of positive RM was 0.1% without any risk factors, increasing to 0.4% with one risk factor, 3.1% with two risk factors, 5.3% with three risk factors, 21.3% with four risk factors, and 85.7% with five risk factors.
CONCLUSIONS
CONCLUSIONS
The risk of macroscopically positive RM increased in patients who have risk factors. IFSD should be performed in patients who have four or more risk factors.
Identifiants
pubmed: 32380979
doi: 10.1186/s12893-020-00744-5
pii: 10.1186/s12893-020-00744-5
pmc: PMC7204060
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
95Références
Ann Surg Oncol. 2016 Apr;23(4):1203-11
pubmed: 26530447
Gastric Cancer. 2002;5(1):1-5
pubmed: 12021853
Gastric Cancer. 2011 Jun;14(2):113-23
pubmed: 21573742
Gastric Cancer. 2012 Sep;15 Suppl 1:S116-24
pubmed: 22138928
World J Surg. 2010 Aug;34(8):1840-6
pubmed: 20407771
Gastric Cancer. 2017 Jan;20(1):70-82
pubmed: 26732876
Gastrointest Endosc. 1997 Sep;46(3):212-6
pubmed: 9378206
J Surg Oncol. 2007 May 1;95(6):461-8
pubmed: 17192913
World J Surg. 2003 Jun;27(6):715-8
pubmed: 12732996
Dig Dis Sci. 1990 Nov;35(11):1340-4
pubmed: 2226095
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Mayo Clin Proc. 1995 Dec;70(12):1137-41
pubmed: 7490913
Ann Surg Oncol. 2014 Aug;21(8):2580-6
pubmed: 24806114
Gastric Cancer. 2018 Jan;21(1):68-73
pubmed: 28194522
Ann Surg Oncol. 2009 Oct;16(10):2738-43
pubmed: 19636636
ANZ J Surg. 2015 Sep;85(9):678-84
pubmed: 24438078
World J Surg. 2008 Dec;32(12):2661-7
pubmed: 18825453
J Surg Oncol. 2016 Mar;113(3):277-82
pubmed: 26662226
Ann Surg Oncol. 2009 Nov;16(11):3028-37
pubmed: 19626373
Br J Surg. 1998 Nov;85(11):1457-9
pubmed: 9823902